NASDAQ:REGN Regeneron Pharmaceuticals (REGN) Stock Price, News & Analysis $721.05 +18.78 (+2.67%) Closing price 04:00 PM EasternExtended Trading$719.60 -1.44 (-0.20%) As of 07:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Regeneron Pharmaceuticals Stock (NASDAQ:REGN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get REGN alerts:Sign Up Key Stats Today's Range$702.50▼$726.1650-Day Range$686.36▼$790.8152-Week Range$476.49▼$821.11Volume739,297 shsAverage Volume747,101 shsMarket Capitalization$76.23 billionP/E Ratio17.57Dividend Yield0.52%Price Target$826.59Consensus RatingModerate Buy Company Overview Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas. Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies. The company operates an integrated model that spans early discovery through late-stage development and commercial production, enabling it to move candidates from laboratory to market using internal capabilities as well as strategic collaborations. Key marketed products and development programs address ophthalmology, immunology, oncology and infectious disease. Regeneron’s marketed medicines include EYLEA (aflibercept) for retinal disorders and Dupixent (dupilumab), developed and co-commercialized in partnership with Sanofi, for certain inflammatory conditions. The company has also developed antibody-based therapies for oncology and infectious disease, including combination antibody treatments for COVID‑19 during the pandemic response. Regeneron serves patients in the United States and internationally through its own commercial operations and partner arrangements. Leadership includes founder and chief executive Leonard S. Schleifer and co‑founder and chief scientific officer George D. Yancopoulos, who have guided the company’s scientific strategy and commercial expansion. Regeneron continues to invest in platform technologies and a diversified pipeline aimed at advancing novel biologic therapies. AI Generated. May Contain Errors. Read More Regeneron Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks86th Percentile Overall ScoreREGN MarketRank™: Regeneron Pharmaceuticals scored higher than 86% of companies evaluated by MarketBeat, and ranked 79th out of 857 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingModerate Buy Consensus RatingRegeneron Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.77, and is based on 2 strong buy ratings, 16 buy ratings, 8 hold ratings, and no sell ratings.Upside PotentialRegeneron Pharmaceuticals has a consensus price target of $826.59, representing about 14.6% upside from its current price of $721.05.Amount of Analyst CoverageRegeneron Pharmaceuticals has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Regeneron Pharmaceuticals' stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth12.65% Earnings GrowthEarnings for Regeneron Pharmaceuticals are expected to grow by 12.65% in the coming year, from $36.85 to $41.51 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Regeneron Pharmaceuticals is 17.57, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.47.Price to Earnings Ratio vs. SectorThe P/E ratio of Regeneron Pharmaceuticals is 17.57, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 29.30.Price to Earnings Growth RatioRegeneron Pharmaceuticals has a PEG Ratio of 1.58. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioRegeneron Pharmaceuticals has a P/B Ratio of 2.43. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted2.89% of the float of Regeneron Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverRegeneron Pharmaceuticals has a short interest ratio ("days to cover") of 4.36.Change versus previous monthShort interest in Regeneron Pharmaceuticals has recently increased by 11.52%, indicating that investor sentiment is decreasing significantly. Dividend1.7 / 5Dividend StrengthWeak Dividend YieldRegeneron Pharmaceuticals has a dividend yield of 0.53%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthRegeneron Pharmaceuticals does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Regeneron Pharmaceuticals is 9.16%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Regeneron Pharmaceuticals will have a dividend payout ratio of 9.06% next year. This indicates that Regeneron Pharmaceuticals will be able to sustain or increase its dividend.Read more about Regeneron Pharmaceuticals' dividend. News and Social Media3.6 / 5News Sentiment0.69 News SentimentRegeneron Pharmaceuticals has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 42 news articles for Regeneron Pharmaceuticals this week, compared to 13 articles on an average week.Search InterestOnly 14 people have searched for REGN on MarketBeat in the last 30 days. This is a decrease of -44% compared to the previous 30 days.MarketBeat Follows18 people have added Regeneron Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 1,700% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Regeneron Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,013,262.00 in company stock.Percentage Held by Insiders6.97% of the stock of Regeneron Pharmaceuticals is held by insiders.Percentage Held by Institutions83.31% of the stock of Regeneron Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Regeneron Pharmaceuticals' insider trading history. Receive REGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. REGN Stock News HeadlinesRARE Q1 Loss Wider Than Expected, Sales Down Y/Y on Seasonal Effect3 hours ago | finance.yahoo.comDupixent® (dupilumab) Demonstrates Improved Esophageal Function in Eosinophilic Esophagitis (EoE) Phase 4 TrialMay 5 at 8:23 AM | finance.yahoo.comI was right about SpaceXJeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,000%. Now he says SpaceX is shaping up to be the biggest IPO of the decade - and three key milestones just confirmed it. In the past 21 days: SpaceX crossed 10,000 active satellites, Elon filed confidential IPO paperwork with the SEC, and another rocket launched 25 more satellites. Two-thirds of every satellite in orbit now belongs to one company. The public filing could drop any day.May 6 at 1:00 AM | Brownstone Research (Ad)Dupixent® (dupilumab) Demonstrates Improved Esophageal Function in Eosinophilic Esophagitis (EoE) Phase 4 TrialMay 5 at 7:00 AM | globenewswire.comArthur Ryan Sells 100 Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) StockMay 5 at 5:23 AM | insidertrades.comHow The Regeneron (REGN) Narrative Is Shifting With Dupixent, Eylea And Pipeline DevelopmentsMay 4 at 7:55 AM | finance.yahoo.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives Average Recommendation of "Moderate Buy" from BrokeragesMay 3 at 2:53 AM | americanbankingnews.comPiper Sandler Rates Regeneron (REGN) Overweight on Oncology GrowthMay 2, 2026 | finance.yahoo.comSee More Headlines REGN Stock Analysis - Frequently Asked Questions How have REGN shares performed this year? Regeneron Pharmaceuticals' stock was trading at $771.87 on January 1st, 2026. Since then, REGN shares have decreased by 6.6% and is now trading at $721.05. How were Regeneron Pharmaceuticals' earnings last quarter? Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) posted its earnings results on Wednesday, April, 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, beating the consensus estimate of $8.91 by $0.56. Regeneron Pharmaceuticals's quarterly revenue was up 19.0% on a year-over-year basis. Read the conference call transcript. Does Regeneron Pharmaceuticals have any subsidiaries? The following companies are subsidiaries of Regeneron Pharmaceuticals: Eastside Campus Holdings LLC, Loop Road Holdings LLC, Old Saw Mill Holdings LLC, OSMR Holdings, Regeneron Assurance Inc., Regeneron Atlantic Holdings, Regeneron Belgium BV, and more. Who are Regeneron Pharmaceuticals' major shareholders? Top institutional shareholders of Regeneron Pharmaceuticals include Bank of New York Mellon Corp (0.72%), Pictet Asset Management Holding SA (0.32%), Sumitomo Mitsui Trust Group Inc. (0.26%) and Swedbank AB (0.20%). Insiders that own company stock include George Yancopoulos, Leonard S Schleifer, Neil Stahl, Andrew J Murphy, Joseph J Larosa, Robert E Landry, Plew Daniel P Van, Arthur F Ryan, Christopher R Fenimore, Marion Mccourt, Joseph L Goldstein, Jason Pitofsky, Christine A Poon, Huda Y Zoghbi, Bonnie L Bassler and Michael S Brown. View institutional ownership trends. How do I buy shares of Regeneron Pharmaceuticals? Shares of REGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Regeneron Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Visa (V). Company Calendar Record date for 3/5 Dividend2/20/2026Ex-Dividend for 3/5 Dividend2/20/2026Dividend Payable3/05/2026Last Earnings4/29/2026Today5/06/2026Bank of America Global Healthcare Conference 20265/12/2026Record date for 6/4 Dividend5/20/2026Ex-Dividend for 6/4 Dividend5/20/2026Dividend Payable6/04/2026Goldman Sachs 47th Annual Global Healthcare Conference 20266/08/2026AGM 20266/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1w+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 For the last 7 days, REGN's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBiotechnology Current SymbolNASDAQ:REGN CIK872589 Webwww.regeneron.com Phone(914) 847-7000Fax914-347-2113Employees15,410Year Founded1988Price Target and Rating Average Price Target for Regeneron Pharmaceuticals$826.59 High Price Target$1,057.00 Low Price Target$255.00 Potential Upside/Downside+14.6%Consensus RatingModerate Buy Rating Score (0-4)2.77 Research Coverage26 Analysts Profitability EPS (Trailing Twelve Months)$41.04 Trailing P/E Ratio17.57 Forward P/E Ratio19.57 P/E Growth1.58Net Income$4.50 billion Net Margins29.65% Pretax Margin34.56% Return on Equity13.16% Return on Assets10.17% Debt Debt-to-Equity Ratio0.06 Current Ratio3.57 Quick Ratio2.96 Sales & Book Value Annual Sales$14.34 billion Price / Sales5.31 Cash Flow$42.67 per share Price / Cash Flow16.90 Book Value$297.23 per share Price / Book2.43Miscellaneous Outstanding Shares105,720,000Free Float98,351,000Market Cap$76.23 billion OptionableOptionable Beta0.30 Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:REGN) was last updated on 5/6/2026 by MarketBeat.com Staff. From Our PartnersYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredThe Iran War Just Broke the Gold MarketThe Iran war isn't just a geopolitical event. It's a financial one. Within hours of the strikes, oil surged...Behind the Markets | SponsoredOne executive order. The biggest wealth transfer of your lifetime.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredBlackRock, JPMorgan, and Goldman are all stock piling the same asset… are you?BlackRock, JPMorgan, Goldman Sachs, Fidelity, ARK Invest and Andreessen Horowitz are all buying the same asset...Awesomely, LLC | SponsoredMilitary ‘Dark Energy’ to Power AIWhen it was put inside U.S. tanks, they moved almost silently and produced no smoke. Now, Elon Musk is using t...Altimetry | SponsoredRevealed: The World’s First Trillion-Dollar RobotJensen Huang stood in Las Vegas and laid out Nvidia's vision for building the world's first trillion-dollar ro...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regeneron Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Regeneron Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free REGN Stock Alerts